MIRM News and Press, Mirum Pharmaceuticals Inc. From 01/07/26

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 11:15 a.m. PT. The presentation and question and answer session will be ...

2026-01-04 04:05:00 ET A year ago, I made five predictions for the stock market in 2025 . Some came true (at least partially), while others didn't. For example, I predicted agentic AI would be a big thing, and that Google parent Alphabet 's (NASDAQ: GOOG) (NASDAQ: GOOG...

2025-12-30 08:14:57 ET More on Takeda Pharmaceutical, XOMA Takeda: Lack Of Realistic Upside In Japanese Pharma Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript Takeda Pharmaceutical Company Limited FY2025 Q2 - Results - Earnings Call Pre...

2025-12-30 03:07:00 ET More than 50 million Americans regularly watch Newsmax (NYSE: NMAX) or read some of its publications. Thanks to a recently announced expansion into Europe and the Middle East, the number of people outside the U.S. who obtain their news from the company is like...

2025-12-22 15:48:33 ET Mirum Investment Overview - Why I Flipped From A Sell To A Buy Rating In March In March this year, I flipped my rating on Mirum Pharmaceuticals, Inc. ( MIRM ) stock from the Sell rating I had given it in October 2024, to a Buy, in a note for Seeking ...

2025-12-22 15:31:36 ET The last time I spoke about Mirum Pharmaceuticals, Inc. ( MIRM ) it was in a Seeking Alpha article entitled "Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value." With respect to this article, I noted that the company had re...

2025-12-19 09:18:52 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. (MIRM) M&A Call Transcript Mirum Pharmaceuticals, Inc. (MIRM) Bluejay Therapeutics, Inc., - M&A Call - Slideshow Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annua...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it has entered into a subscription agreement with entities associated with TCGX, an institutional investor, for a private placement of 1,000,000 shares of its common stock (the “Common Stock&#x...

2025-12-10 16:06:16 ET from Leerink Partners issued a price target of $100.00 for MIRM on 2025-12-10 20:13:33. The adjusted price target was set to $100.00. At the time of the announcement, MIRM was trading at $64.67. The overall price target consensus is at $96.00 with ...

2025-12-09 08:15:11 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for MIRM on December 9, 2025 12:56PM ET. The previous analyst recommendation was Overweight. MIRM was trading at $67.9 at issue of the analyst recommendation. The overall analyst consensus : B...